94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
CASE REPORT article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1567149
This article is part of the Research TopicInnovative Immunotherapy Strategies for Enhanced Treatment of Hodgkin and Non-Hodgkin LymphomasView all 11 articles
Case Report: Bispecific CD20/CD30-targeted Chimeric Antigen Receptor T-cell Therapy for Non-Hodgkin's Lymphoma
Provisionally accepted- 1Department of Hematology, Affiliated Hospital of Nantong University, Nantong, China
- 2TriArm Therapeutics (Shanhai), Shanghai, China
- 3Shanghai First Song Therapeutics, Shanghai, China
- 4TriArm Inc., California, United States
- 5Department of General Surgery, Affiliated Hospital of Nantong University, Nantong, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
CD19-directed CAR T-cell therapy is a breakthrough immunotherapy for B-cell malignancies. However, CD19 loss-mediated relapsed/refractory disease continues to pose a significant challenge, highlighting the urgent need for CAR T cells targeting alternative antigens. To address this issue, we developed a CD20-directed CAR T incorporated with an additional CD30-directed binder to enhance cytotoxicity toward cancer cells. Here, we report that a patient with bulky transformed follicular lymphoma was successfully treated with CD20/CD30-directed CAR-T cells. The patient received two doses of anti-CD20/CD30-CAR-T therapy administered one month apart. Complete metabolic remission was achieved 1 month after the first infusion without evidence of cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS). The second dose was given as a consolidation therapy with sustained disease-free survival exceeding 12 months to date. The report underscores the promising therapeutic potential and safety profile of CD20/CD30directed CAR T-cell therapy.
Keywords: CAR T-cell therapy, Transformed follicular lymphoma, CD20, CD30, Bispecific
Received: 26 Jan 2025; Accepted: 14 Apr 2025.
Copyright: © 2025 Huang, Gong, Liu, Ruan, Lu, Kouros- Mehr, Liu and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Hong Liu, Department of Hematology, Affiliated Hospital of Nantong University, Nantong, China
Han Wang, Department of General Surgery, Affiliated Hospital of Nantong University, Nantong, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.